^
HIF1A overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive
:
B
ESMO-BC 2021 - 1wk
BACH1 overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive
:
B
ESMO-BC 2021 - 1wk
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive
:
C3
ESMO-BC 2021 - 1wk
ER positive + PGR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive
:
C3
ESMO-BC 2021 - 1wk
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + alpelisib + LJM-716
Sensitive
:
C3
Clin Cancer Res - 1wk
MYC underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
HER-2 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
FOXA1 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
MIA underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT5 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
CDH3 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT17 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
SFRP1 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
CXXC5 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
GPR160 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
MLPH overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
GRB7 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT14 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
CD276 overexpression
Triple Negative Breast Cancer
B7H3-targeted CAR-T immunotherapy
Sensitive
:
D
ASGCT 2021 - 2wk
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive
:
C3
NPJ Breast Cancer - 3wk
CCNA2 overexpression
Breast Cancer
Immunotherapy
Sensitive
:
C3
Onco Targets Ther - 4wk
BRCA1 mutation
Triple Negative Breast Cancer
olaparib + palbociclib
Sensitive
:
D
J Exp Clin Cancer Res - 4wk
HASPIN expression
Breast Cancer
CHR-6494
Sensitive
:
D
PLoS One - 4wk
BRCA2 mutation
Triple Negative Breast Cancer
olaparib + palbociclib
Sensitive
:
D
J Exp Clin Cancer Res - 4wk
RB1 negative
Triple Negative Breast Cancer
VRN08
Sensitive
:
D
AACR 2021 - 4wk
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide intravenous
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Breast Cancer
TAC
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our